Mephenytoin

CHEMBL861 Phase 4 Approved Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

218.2 g/mol

LogP

1.5

Phase

4

An anticonvulsant related to phenytoin used to control certain types of seizures in patients who have not responded to safer first-line antiepileptic drugs. It carries a higher risk of serious side effects compared to other seizure medications and is rarely used today.

Molecular Weight

218.2500 g/mol

LogP

1.50

TPSA

49.40 Å²

Lipinski RO5

Pass

Mechanism of Action

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of …

2D Structure

SVG PNG

Cite this structure

Embed this structure

SMILES

CCC1(c2ccccc2)NC(=O)N(C)C1=O

InChI

InChI=1S/C12H14N2O2/c1-3-12(9-7-5-4-6-8-9)10(15)14(2)11(16)13-12/h4-8H,3H2,1-2H3,(H,13,16)

Molecular Formula

C12H14N2O2

HBD / HBA

1 / 2

Rotatable Bonds

2

Heavy Atoms

16

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

An anticonvulsant related to phenytoin used to control certain types of seizures in patients who have not responded to safer first-line antiepileptic drugs. It carries a higher risk of serious side effects compared to other seizure medications and is rarely used today.

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Yes, Mephenytoin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL861. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 4060. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Looking for patient-friendly information?

Mephenytoin on PillFYI

Structure

Quick Data

Formula: C12H14N2O2

External Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.